The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.
Chlorpheniramine maleate 4mg, dextromethorphan HBr 30mg; tabs. Drowsiness, anticholinergic effects, excitability in children.
The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.
At all time points, consistently high levels of patient satisfaction were observed (>84% reporting much or very much improved).
If the proposed policy had taken effect, it would have only reimbursed doctors based on time limits set by the insurer.
The FDA is expected to decide on treatments for EBV-positive posttransplant lymphoproliferative disease, breast cancer, Barth syndrome, pain, and migraine.
The single-arm, open-label APPULSE-PNH trial included 52 PNH patients who were on a stable regimen with either eculizumab or ravulizumab.
(HealthDay News) — Increased consumption of dark chocolate, but not milk chocolate, is associated with a reduced risk for type 2 diabetes (T2D), according to a study published online Dec. 4 in The BMJ ...
Diclofenac sodium 2% (delivers 20mg per pump actuation); topical soln. Pennsaid (diclofenac sodium) topical solution 2% w/w, is supplied as a clear, colorless to faintly pink or orange solution ...
Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens.
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
B, Recombivax HB, or Twinrix as hepatitis B vaccination recommendations that providers can give pregnant patients.